EGFR and non-small cell lung carcinoma: A recent research conducted by the Japanese Joint Committee of Lung Cancer Registry reported that with EGFR mutation exhibited a significant improvement in DFS (HR, 0.894; 95%CI, 0.814–0.980; p = 0.017) and OS (HR, 0.729; 95%CI, 0.642–0.829; p < 0.001) in a cohort comprising 5780 patients who underwent surgical resection for early-stage NSCLC [29].